Isotechnika to Host Educational Symposium at the American Transplant Congress

Edmonton, Alberta (ots/PRNewswire) - Isotechnika will host an
evening educational symposium at the American Transplant Congress.
The evening symposium titled "Unleashing the Power of CNi's" will
take place on Saturday, May 5th at 7:30 p.m. at the San Francisco
Marriott Hotel.

The symposium will highlight the use of ISA247 for the prevention
of transplant organ rejection. The evening will focus on the use of
calcineurin inhibitors, the design of ISA247, and the potential for
this design to result in improvements in both safety and efficacy
for transplant and psoriasis patients. The latest results from the
North American Phase 2b kidney transplant (PROMISE) trial will also
be presented. The symposium will also provide attendees the
opportunity to meet clinical trial investigators currently involved
in the Company's PROMISE trial. The topics to be discussed can be
found at www.isotechnika.com/symposium.

"We are pleased to be given the opportunity to host a symposium at
one of the most prestigious transplant meetings worldwide," stated
Dr. Randall Yatscoff, Isotechnika's President & CEO. "This symposium
is the perfect forum to present the potential of ISA247 in
transplantation to transplant surgeons and physicians already
familiar with current calcineurin inhibitors."

The formal presentations from the evening symposium will be
recorded and available to all interested parties on Isotechnika's
corporate web site by visiting www.isotechnika.com starting Monday,
May 7th.

North American Phase 2b Kidney Transplant Study Design

Forty-one centers across North America have been contracted to
perform the trial, including thirty-seven centers in the United
States and four centers in Canada. The primary endpoint of the trial
is defined as non-inferiority in biopsy proven acute rejection
(BPAR) episodes in patients receiving ISA247 for six months as
compared to the tacrolimus control which is currently the North
American leading transplant drug in this class. Additionally, kidney
function and other laboratory parameters will be monitored for the
duration of the trial. The overall goal of the trial is to find the
most appropriate dose that will result in efficacy (lack of acute
rejection) with minimal side effects that are typically seen with
other calcineurin inhibitors such as cyclosporine and tacrolimus.

A total of 332 de novo (newly transplanted) kidney transplant
patients will be enrolled in this trial. Patients will be placed
into one of four separate treatment groups; three different dose
groups of ISA247 (0.4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg twice daily
compared with the fourth group, a tacrolimus (0.05 mg/kg twice
daily) control arm. Patients in all four treatment groups will have
their doses adjusted in order to achieve pre-defined blood levels of
either ISA247 or tacrolimus. All patients will receive treatment
over a six month period along with other standard immunosuppressive
therapies used following transplantation. Patients completing the
six month trial will be given the option to continue therapy for one
year. The objective is to gather long term safety and efficacy data
in de novo transplant patients.

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies. Isotechnika's
lead compound, ISA247 has successfully completed a Phase 3 Canadian
trial for the treatment of moderate to severe psoriasis. ISA247 is
currently being investigated in a combined Phase 3 European/Canadian
psoriasis trial and a Phase 2b North American trial for the
prevention of kidney graft rejection. Our partner, Lux Biosciences
has received permission from the Food and Drug Administration to
investigate ISA247 in three separate pivotal Phase 2/Phase 3 trials
for the treatment of non-infectious uveitis and as a maintenance
therapy in uveitis. The Company also successfully completed Phase 1
clinical trials of an additional immunosuppressive compound in its
drug pipeline, TAFA93.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize voclosporine for all transplant
indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of voclosporine and TAFA93 specifically with drug eluting
devices for the non-systemic treatment of vascular, cardiovascular,
target vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of voclosporine in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, voclosporine for the treatment and prophylaxis of all
ophthalmic diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr.Randall Yatscoff, President & CEO,
Isotechnika Inc., Phone: +1-780-487-1600 Ext.246, Fax:
+1-780-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-780-487-1600 Ext.243, Fax: +1-780-484-4105, E-mail:
sgillis-paulgaard@isotechnika.com (ISA.)